相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1954
招募中
3
100.0%
暂无批准数据
- The Precision Platform, led by Sahlgrenska University Hospital with academic and industry partners, aims to shorten the path from research to clinical implementation in precision health. - A Health Data Sandbox will be established as a secure environment for developing AI-based clinical decision support systems, diagnostic tools, and data-driven solutions. - A pre-GMP laboratory will strengthen the region's capacity to develop and scale up advanced therapy medicinal products (ATMPs) from early innovation to clinical application. - The initiative seeks to position Western Sweden as a leading European innovation hub for precision health, attracting talent, investment, and international partnerships.
- Researchers at Chalmers University and University of Gothenburg developed BayesCNA, a statistical method that detects cancer DNA in blood at levels as low as 5%, compared to the current 15–20% threshold. - The method uses classical statistics rather than machine learning to amplify weak signals from low-pass whole-genome sequencing, a cost-effective but low-resolution technique. - BayesCNA could enable closer monitoring of tumor progression between treatment sessions, helping doctors tailor therapies based on tumor composition changes over time. - The research team aims to further develop the method for identifying hidden cancer characteristics and hopes to advance toward clinical trial applications.
- Tirzepatide, the active ingredient in Mounjaro, reduced voluntary alcohol consumption by more than half in animal models and prevented relapse-like drinking behaviors. - The dual GIP/GLP-1 receptor agonist appears to work by attenuating alcohol-induced dopamine effects in the brain's reward system, particularly in the lateral septum region. - Researchers identified changes in histone-related proteins in the lateral septum, suggesting potential long-term biological mechanisms underlying the drug's effects on addiction pathways. - The findings support further investigation of tirzepatide as a potential treatment for alcohol use disorder, leveraging its established clinical safety profile from diabetes and obesity applications.
- Researchers at the University of Gothenburg found that semaglutide, a diabetes and weight loss medication, reduced cocaine self-administration by 26% in rats compared to control animals. - The study demonstrated a 62% reduction in cocaine-seeking behavior after abstinence and a 52% decrease in motivation to obtain the drug in semaglutide-treated animals. - These findings represent the first preclinical evidence that semaglutide could potentially address cocaine dependency, for which no effective pharmacological treatments currently exist. - Clinical trials in humans are needed to confirm whether these promising animal study results translate to therapeutic benefits for cocaine addiction treatment.
- The SWEDEPAD 1 and 2 trials found that paclitaxel-coated stents and balloons did not reduce amputation risk or improve quality of life compared to uncoated devices in peripheral artery disease patients. - In chronic limb-threatening ischemia patients, drug-coated devices showed no significant difference in time to amputation over 5 years of follow-up despite initial reductions in target vessel reinterventions. - Patients with intermittent claudication showed no quality of life improvements with drug-coated devices, and a concerning signal of increased 5-year mortality was observed. - The findings challenge the clinical value of expensive paclitaxel-coated devices and suggest clinicians should carefully evaluate risks and benefits before use.
- Researchers at Fraunhofer ITEM have demonstrated for the first time that drug concentrations in human lungs can be measured directly using particles in exhaled breath, marking a significant breakthrough for inhaled therapy development. - The study showed that exhaled breath particles (PEx) provided clear pharmacokinetic profiles with significantly higher drug concentrations compared to nasal or blood samples after salbutamol inhalation. - This non-invasive method enables direct measurement of drug levels within the epithelial lining fluid of lungs, representing a milestone for optimizing inhaled treatments. - The groundbreaking research earned Prof. Jens Hohlfeld and Dr. Olaf Holz the prestigious Willi Stahlhofen Award from the International Society for Aerosols in Medicine.
- A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications. - The combination therapy significantly reduced alcohol consumption and cravings by targeting dopamine deficiency, which researchers hypothesize drives alcohol craving behavior. - Patients receiving the combination treatment experienced less nausea and shorter symptom duration compared to varenicline alone, potentially improving treatment completion rates. - The study provides pharmacological support for the dopamine deficiency hypothesis of alcohol use disorder and represents a significant advancement in addressing this condition that can reduce life expectancy by 25 years or more.
- Individuals with Down syndrome face significantly higher risks of stroke, with hemorrhagic stroke risk 5.14 times higher and ischemic stroke risk 4.41 times higher than the general population. - Young adults with Down syndrome (under 40) show an increased risk of acute myocardial infarction, suggesting a different cardiovascular risk profile than typically developing individuals. - The presence of atherosclerotic and embolic risk factors further elevates stroke risk in Down syndrome patients, highlighting the need for specialized screening and prevention strategies.
- A clinical trial presented at the European Respiratory Society Congress 2024 suggests sulthiame, an epilepsy drug, reduces sleep apnea symptoms. - Patients taking sulthiame experienced fewer breathing interruptions during sleep and improved blood oxygen levels compared to placebo. - The study involved nearly 300 participants with OSA who could not tolerate CPAP machines, showing a potential alternative treatment. - Further trials are needed to confirm these benefits before sulthiame can be widely adopted as a treatment for sleep apnea.
